T
Tina Garyantes
Publications - 6
Citations - 1028
Tina Garyantes is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 871 citations.
Papers
More filters
Journal ArticleDOI
Impact of high-throughput screening in biomedical research
Ricardo Macarron,Martyn Banks,Dejan Bojanic,David J. Burns,Dragan A. Cirovic,Tina Garyantes,Darren V. S. Green,Robert P. Hertzberg,William P. Janzen,Jeff W. Paslay,Ulrich Schopfer,G. Sitta Sittampalam +11 more
TL;DR: The case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes is presented.
Journal ArticleDOI
Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.
Carolyn Y. Muller,Marya F. Chaney,Justine V. Cohen,Tina Garyantes,Jessica Lin,Patricia LoRusso,Alain C. Mita,Monica M. Mita,Christopher Natale,Marlana Orloff,Kyriakos P. Papadopoulos,Sapna Pradyuman Patel,Jordi Rodon Ahnert +12 more
TL;DR: The combination of LNS8801 and pembrolizumab is tolerable without unanticipated toxicities and demonstrates encouraging anti-tumor activity in patients that are r/r to ICIs, as well as continued follow-up on patients with long-term benefit from dose escalation, support further development of L NS8801 as a cancer therapeutic.
Journal ArticleDOI
85P A circulating, surrogate-systemic biomarker correlates with anti-tumor benefit on LNS8801 therapy
Joshua G. Cohen,Christopher A. Natale,J. Lin,P. Lorusso,Alan Mita,Monica M. Mita,Carolyn Y. Muller,Marlana Orloff,Kyri Papadopoulos,Jordi Rodon,Tina Garyantes +10 more
TL;DR: LNS8801 as mentioned in this paper is an oral, highly selective agonist of the G protein-coupled estrogen receptor (GPER), which normalizes c-Myc levels in cancer cells, inhibits proliferation, suppresses invasion and enhances immune recognition.
Journal ArticleDOI
The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.
Alexander N. Shoushtari,Marya F. Chaney,Justine V. Cohen,Tina Garyantes,Jessica Lin,Jeffrey J. Ishizuka,Alain C. Mita,Monica M. Mita,Carolyn Muller,Christopher Natale,Marlana Orloff,Kyriakos P. Papadopoulos,Sapna Pradyuman Patel,Jordi Rodon Ahnert +13 more
TL;DR: In this article , LNS8801 (125 mg, QD, PO) alone or in combination with pembrolizumab (200 mg, IV, Q3W, IV) was used for metastatic uveal melanoma (mUM) patients.
Journal ArticleDOI
The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells
TL;DR: In this article , the role of G protein-coupled estrogen receptor-1 (GPER) in uveal melanoma cells was investigated and it was shown that downregulation of GPER decreased expression of p53 and stimulated cell growth.